Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Infinity Pharmaceuticals Ends Rheumatoid Arthritis Treatment Study

By Pharmaceutical Processing | January 8, 2015

CAMBRIDGE, Mass. (AP) — Infinity Pharmaceuticals will stop studying one of its potential drugs as a rheumatoid arthritis treatment after it failed to generate enough improvement in patients during a mid-stage study.

Shares of the Cambridge, Massachusetts, company tumbled early Thursday morning after it announced the discontinuation but said it still plans to study the drug, duvelisib, as a potential treatment for blood cancers like leukemia and non-Hodgkin lymphoma. It is collaborating with fellow drug developer AbbieVie Inc. on those potential treatments.

Infinity was studying duvelisib in patients with moderate-to-severe forms of rheumatoid arthritis, a chronic inflammatory disease that affects the joints and destroys soft tissue, cartilage and bone. More than 300 patients in the study received a combination of either duvelisib and another drug, methotrexate, or a fake drug and methotrexate.

The drug fell short of the study’s main goal of generating a certain rate of improvement after three months of treatment.

Rheumatoid arthritis represents a major area of research for drug companies because it is chronic, meaning patients will likely take the drugs regularly for a long time.

Infinity Pharmaceuticals Inc. shares were down 11 percent, or $1.81, to $14.50 more than an hour before markets opened. The stock had climbed about 30 percent last year.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE